| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
23068 |
| Drug |
Linzagolix |
| Brand |
Yselty® |
| Indication |
Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. |
| Rapid review commissioned |
09/11/2023 |
| Rapid review completed |
19/12/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of linzagolix compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/01/2024 |
| Pre-submission consultation with Applicant |
16/04/2024 |
